8-(4-bromo-2,6-dimethyl-phenyl)-4-chloro-2-methyl-pyrrolo[1,2-a]pyrimidine-6-carbonitrile | 860012-67-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 8-(4-bromo-2,6-dimethyl-phenyl)-4-chloro-2-methyl-pyrrolo[1,2-a]pyrimidine-6-carbonitrile
• 英文别名: 8-(4-bromo-2,6-dimethylphenyl)-4-chloro-2-methylpyrrolo[1,2-a]pyrimidine-6-carbonitrile
• CAS: 860012-67-5
• 化学式: C₁₇H₁₃BrClN₃
• 分子量: 374.667
• InChiKey: KTMQLQLPDZGWJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-(4-bromo-2,6-dimethyl-phenyl)-4-chloro-2-methyl-pyrrolo[1,2-a]pyrimidine-6-carbonitrile 在 硫脲 、 sodium hydroxide 、 水 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 8-(4-bromo-2,6-dimethyl-phenyl)-4-mercapto-2-methyl-pyrrolo[1,2-a]pyrimidine-6-carbonitrile
  参考文献：
  名称：

  [EN] PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS
  [FR] DERIVES DE PYRROLOPYRIMIDINE ET DE PYRROLOTRIAZINE

  摘要：

  公开号：

  WO2005066142A3

文献信息

• Pyrrolopyrimidine and pyrrolotriazine derivatives
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US08106194B2

  公开（公告）日：2012-01-31

  An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  本发明的目的是提供一种CRF受体拮抗剂，该拮抗剂可作为治疗或预防剂用于与CRF有关的疾病，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、癫痫、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮肤炎、精神分裂症、疼痛等。具有以下式[I]所表示的羰胺基取代的吡咯吡嘧啶或吡咯三嗪衍生物对CRF受体具有高亲和力，并对与CRF有关的疾病有效。
• PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES
  申请人：Nakazato Atsuro

  公开号：US20110137031A1

  公开（公告）日：2011-06-09

  An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  本发明的目的是提供一种针对CRF受体的拮抗剂，该拮抗剂可作为治疗或预防剂用于CRF参与的疾病，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、癫痫、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮肤炎、精神分裂症、疼痛等。以下式[I]所示的带有氨基甲酰基取代的吡咯吡嘧啶或吡咯三嗪衍生物具有高亲和力，对于CRF参与的疾病具有有效作用。
• US8106194B2
  申请人：——

  公开号：US8106194B2

  公开（公告）日：2012-01-31
• [EN] PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PYRROLOPYRIMIDINE ET DE PYRROLOTRIAZINE
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2005066142A3

  公开（公告）日：2005-10-13